Life sciences venture capital firm Forbion announced on Tuesday it has raised a record €2.3 billion ($2.6 billion) for two new funds, a major capital injection that stands in stark contrast to a broader downturn in European venture fundraising. The successful raise, which the firm said was its largest to date, signals powerful investor confidence in specialist biotech investors even as the continent faces what Forbion and other market observers describe as a "general shortage of capital."
The fundraising substantially exceeded its initial target and was completed "at pace," according to a statement from the Netherlands-based firm. This influx of capital brings Forbion's total assets under management to approximately €7.5 billion, an increase of 50% in just two years. The firm noted the total represents one of the largest life sciences venture capital fundraisings globally over the last five years, positioning it to significantly influence the direction of European biotech innovation.
A Counter-Signal in a Contracting Market
Forbion's success arrives amidst a challenging environment for venture capital in Europe. While global VC fundraising is on pace for a rebound from 2025, the recovery is highly uneven. According to a recent report from Pitchbook cited by MedCity News, Europe is on pace for its lowest fundraising total since 2019, excluding the previous year. This trend highlights a growing "venture capital gap" between Europe and other regions.
The Pitchbook report clarifies that strong activity in North America is masking weakness elsewhere. While global deal values are up year-over-year, every other region, including Europe, is on track for a decline in the number of deals. This downturn is attributed to a lack of liquidity across global markets, creating a capital-starved environment for many European startups and a difficult fundraising climate for the venture firms that support them.
Forbion's Fundraise vs. European VC Trends (2026)
The contrast between Forbion's landmark achievement and the prevailing market conditions illustrates its exceptional position. The following table juxtaposes the firm's results with the broader trends shaping the European venture landscape this year, based on company announcements and third-party market analysis.
| Metric | Forbion's Fundraise (October 2026) | European VC Market Trend (2026) |
|---|---|---|
| Total Capital Raised | €2.3 billion ($2.6 billion) across two funds, the firm's largest to date. | On pace for the lowest fundraising total since 2019, excluding the previous year, according to a Pitchbook report. |
| Market Dynamics | Fundraising substantially exceeded its target and was conducted "at pace," reflecting strong investor demand. | Characterized by a "general shortage of capital" and a lack of liquidity across global markets, as noted by Pitchbook. |
| Regional Performance | Attracted significant international capital, with 40% of funds from North American investors. | Lags North America in deal activity and values; on pace for a year-over-year decline in deal count. |
Global Investors Bet on Proven Performance
The success of the fundraise demonstrates a flight to quality among institutional investors. In a constrained market, capital is flowing to established managers with a strong track record. A report in The Wall Street Journal noted that while approximately 60% of the capital came from European investors, a significant 40% was sourced from North America. This transatlantic backing signals a global conviction in Forbion's strategy, even amid regional headwinds.
Forbion's announcement named a roster of high-caliber institutional and corporate backers, including Dutch pension managers MN and PGGM, Germany’s state-backed KfW Capital, and the corporate venture arm of Eli Lilly and Company. Reporting from Dealroom framed the raise as clear evidence that "major investors continue to support specialist managers with proven performance." In a more challenging biotech financing environment, Forbion's 20-year history appears to have provided the assurance that large, long-term investors require.
New Capital to Fuel European Innovation
The new capital is allocated to two distinct vehicles: Forbion Growth Opportunities Fund IV, aimed at later-stage companies, and Forbion Ventures Fund VIII, focused on earlier-stage ventures. Together, these funds are expected to provide financing to approximately 30 high-potential biotech companies. Forbion confirmed that the first investments from the new funds have already been completed, indicating a swift deployment of capital into the ecosystem.
This strategy directly addresses the funding gap that can stall promising European science. By providing capital across the company lifecycle, Forbion can nurture startups from their early stages through to maturity. In its own words, the firm now has "significant dry powder" that allows it to "select the most exciting biotech companies for investment." This financial strength provides a strategic advantage, enabling Forbion to build and scale companies developing what it calls "paradigm-shifting treatments" for unmet medical needs.
What Forbion's Fundraise Signals for European Biotech
The successful and globally-backed fundraise by Forbion demonstrates that significant capital can still be attracted to the European life sciences sector, particularly by specialist firms with a proven track record, even amidst a broader market downturn. While not indicative of a market-wide recovery, the event provides a crucial boost of confidence and, more importantly, capital for an industry navigating a difficult funding climate. It suggests a bifurcation in the market, where top-tier managers can command investor attention while others may continue to struggle.
For the European biotech ecosystem, the key development to watch is the deployment of Forbion's new funds into specific European biotech companies and observe if this event encourages a broader rebound or increased investor confidence in other European life sciences venture funds in the coming quarters.
